Jingelai ^® The mechanism of action is to antagonize platelet activating factor (PAF), inhibit platelet aggregation, resist excitotoxicity, anti-inflammatory, protect brain capillary endothelium, antioxidant, and inhibit neuronal apoptosis to protect neurovascular units.

Jingelai ^® After its launch, tens of thousands of clinical evidence have confirmed that ginkgolide injection is safe, effective, and economical. The key evidence-based studies include the GIANT study of 1113 cases of ginkgolide injection combined with intravenous thrombolysis to improve neurological function in AIS patients, the GISAA study of 949 cases of ginkgolide injection in the treatment of atherosclerotic ischemic stroke, retrospective real world study, safety study, etc.

Jingelai ^® Received consensus recommendations from multiple guidelines, including the Chinese Medical Association's "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023", the Chinese Stroke Association's "Clinical Management Guidelines for Cerebrovascular Disease in China" (first edition in 2019, second edition in 2023), and the National Health Commission's Stroke Prevention and Control Engineering Committee's "Chinese Stroke Prevention and Control Standards (second edition)" (2021).